JAK2 Mutation Testing in Myeloproliferative Neoplasms – Guideline Summary

When to Order JAK2 Testing

• Test for the JAK2 V617F mutation immediately in any patient with unexplained erythrocytosis (hemoglobin > 16.5 g/dL in women or > 18.5 g/dL in men), persistent thrombocytosis (platelets ≥ 450 × 10⁹/L), or clinical suspicion of a myeloproliferative neoplasm (e.g., splenomegaly, constitutional symptoms, unexplained leukocytosis). – World Health Organization (WHO) thresholds; Evidence level: not specified [1][2]

• Unexplained elevation of hemoglobin/hematocrit that meets WHO diagnostic thresholds for polycythemia vera is a primary indication for JAK2 testing. – WHO; Evidence level: not specified [1][2]

• Sustained thrombocytosis ≥ 450 × 10⁹/L without an obvious reactive cause warrants JAK2 testing. – WHO; Evidence level: not specified [1][2]

• Clinical suspicion of a myeloproliferative neoplasm based on splenomegaly, constitutional symptoms, or unexplained leukocytosis also justifies testing. – National Comprehensive Cancer Network (NCCN); Evidence level: not specified 3

Diagnostic Utility by Disease

Polycythemia Vera (PV)

• JAK2 V617F is detected in > 95 % of PV cases, making it the principal molecular diagnostic marker. – WHO; Evidence level: not specified 1

• JAK2 mutation testing is a WHO major diagnostic criterion for PV. – WHO; Evidence level: not specified [1][2]

Essential Thrombocythemia (ET)

• JAK2 V617F is present in approximately 50–60 % of ET cases. – NCCN; Evidence level: not specified 3

• Demonstration of JAK2 V617F or another clonal marker (e.g., CALR, MPL) is required as the fourth WHO major diagnostic criterion for ET. – WHO; Evidence level: not specified [1][2]

• When JAK2 V617F is absent, testing must exclude reactive thrombocytosis and identify alternative clonal markers such as CALR or MPL. – WHO; Evidence level: not specified [1][2]

Primary Myelofibrosis (PMF)

• JAK2 V617F is found in approximately 50 % of PMF cases. – WHO; Evidence level: not specified 1

• JAK2 mutation serves as the third WHO major diagnostic criterion for PMF, confirming clonality and ruling out reactive marrow fibrosis. – WHO; Evidence level: not specified [1][4]

• CALR mutations are associated with improved overall survival compared with JAK2‑mutated or triple‑negative disease. – NCCN; Evidence level: not specified 3

Interpretation of Test Results

• A positive JAK2 V617F result confirms a clonal myeloproliferative process and excludes reactive causes. – WHO; Evidence level: not specified [1][4]

• JAK2 V617F positivity alone cannot differentiate PV, ET, or PMF; integration of clinical features, complete blood counts, and bone‑marrow histology is required. – WHO; Evidence level: not specified [1][4]

• A negative JAK2 V617F result does not rule out a myeloproliferative neoplasm; further molecular testing for JAK2 exon 12 (in erythrocytosis), MPL, and CALR should be pursued. – WHO; Evidence level: not specified [1][4]

• Reactive thrombocytosis does not preclude an ET diagnosis if WHO criteria—including JAK2 positivity—are satisfied. – WHO; Evidence level: not specified [1][4]

Risk Stratification & Management Implications

• JAK2 mutation status does not alter the primary risk‑stratification algorithms for PV and ET; age > 60 years and prior thrombotic events remain the main high‑risk factors. – NCCN; Evidence level: not specified 3

• In PMF, patients harboring JAK2 V617F have a higher thrombotic risk than those with CALR mutations. – NCCN; Evidence level: not specified 3

• JAK2 inhibitors (e.g., ruxolitinib) are indicated for symptomatic splenomegaly or constitutional symptoms in myelofibrosis, independent of mutation status. – NCCN; Evidence level: not specified 3

Management of JAK2 V617F Mutation

Initial Diagnostic Workup

• The American College of Hematology recommends a complete blood count with differential to assess for erythrocytosis, thrombocytosis, or leukocytosis in patients with JAK2 V617F mutation 5, 6
• A peripheral blood smear examination is necessary for morphological abnormalities in patients with JAK2 V617F mutation 7
• Bone marrow aspirate and biopsy with reticulin staining is required to distinguish between polycythemia vera, essential thrombocythemia, and primary myelofibrosis in patients with JAK2 V617F mutation 5, 6
• Serum erythropoietin level is typically suppressed in polycythemia vera patients with JAK2 V617F mutation 5
• A comprehensive metabolic panel, including LDH, uric acid, and liver function tests, is necessary for patients with JAK2 V617F mutation 5
• Assessment of spleen size by palpation is required for patients with JAK2 V617F mutation 5, 6
• Coagulation studies are necessary to evaluate for acquired von Willebrand disease in patients with JAK2 V617F mutation and platelets >1000 × 10⁹/L 5

Risk Stratification

• The National Comprehensive Cancer Network recommends classifying patients with polycythemia vera or essential thrombocythemia as high-risk if they have a prior history of thrombosis or are aged >60 years 8, 9
• The revised IPSET-Thrombosis score refines essential thrombocythemia risk stratification into four categories: very low risk, low risk, intermediate risk, and high risk 10, 11
• The International Prognostic Scoring System (IPSS) or Dynamic IPSS (DIPSS) is used to stratify primary myelofibrosis patients, incorporating factors such as age, constitutional symptoms, hemoglobin level, leukocyte count, and peripheral blood blasts 12, 9

Treatment Approach

• The American Society of Hematology recommends initiating all three components of therapy, including phlebotomy, low-dose aspirin, and cytoreductive therapy, for high-risk polycythemia vera patients with JAK2 V617F mutation 8, 13, 9
• Low-dose aspirin and phlebotomy are recommended for low-risk polycythemia vera patients with JAK2 V617F mutation 8, 9
• Cytoreductive therapy with hydroxyurea is recommended for high-risk essential thrombocythemia patients with JAK2 V617F mutation 8, 9
• Low-dose aspirin is recommended for low-risk essential thrombocythemia patients with JAK2 V617F mutation 10, 11
• JAK inhibitors, such as ruxolitinib, are recommended for symptomatic splenomegaly, constitutional symptoms, or intermediate-2/high-risk primary myelofibrosis patients with JAK2 V617F mutation 5, 6

Special Clinical Situations

• The American College of Obstetricians and Gynecologists recommends a management protocol for pregnant women with JAK2 V617F mutation, including low-dose aspirin, phlebotomy, and cytoreductive therapy if needed 13, 6
• Patients with JAK2 V617F mutation face a 7.7% risk of vascular occlusion and 7.3% risk of major hemorrhage perioperatively, and require optimized platelet count and hematocrit before elective surgery 13
• Anticoagulation with low molecular weight heparin is recommended for patients with JAK2 V617F mutation and thrombosis 6, 13

Monitoring and Follow-Up

• Regular monitoring every 3-6 months is recommended for all patients with JAK2 V617F mutation, including complete blood count with differential, assessment of disease-related symptoms, spleen size evaluation, and evaluation for thrombotic or hemorrhagic complications 5, 6, 9
• Serial JAK2 V617F allele burden measurement has clinical utility for predicting complications, and monitoring allele burden annually or when hematologic parameters change significantly is recommended 7
• Bone marrow biopsy is recommended if patients have progressive splenomegaly, new or worsening cytopenias, constitutional symptoms, or increasing LDH 5, 11